CNS Pharmaceuticals Inc (CNSP NASDAQ) stock market data APIs
$5.7847
0(0%)
as of September 11, 2026
Try our APIs with
free plan!
CNS Pharmaceuticals Inc Financial Data Overview
Price chart is built with
Anychart
CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of therapies for neurology and oncology diseases in the United States. It develops TPI 287, an investigational chemotherapy agent, which is in Phase II clinical trial for the treatment of glioblastoma, metastatic breast cancer with brain metastases, non-small cell lung cancer, castration-resistant prostate cancer, and neuroblastoma; and Berubicin, an investigational anthracycline chemotherapy agent, which is in Phase II clinical trial for the treatment of glioblastoma and brain tumors. The company was incorporated in 2017 and is headquartered in Houston, Texas.
Prev. Close
5.7847
Open
5.7886
High
5.789
Low
5.7383
52 wk Range
1.9-10.588
Market Cap
8 535 K
Shares Outstanding
1 461 K
EPS
-0.38
Beta
0.997
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get CNS Pharmaceuticals Inc data using free add-ons & libraries
Get CNS Pharmaceuticals Inc Fundamental Data
CNS Pharmaceuticals Inc Fundamental data includes:
- Net Revenue:
- EBITDA: -16 899 640
- Earnings Per Share: -15
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-08-12
- EPS/Forecast: -0.24
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
CNS Pharmaceuticals Inc News
New
CNS Pharmaceuticals GAAP EPS of -$0.37 misses by $0.13
* CNS Pharmaceuticals press release [https://seekingalpha.com/pr/20616415-cns-pharmaceuticals-reports-second-quarter-2026-results-highlighting-strengthened-balance] (CNSP [https://seekingalpha.com/s...
Forget the 242% Biotech Meme. This Brain Cancer Stock Has a $38 Analyst Target and Trades at $6
Quick Read NeOnc and Plus Therapeutics operate in the same CNS oncology space as CNS Pharmaceuticals but carry deeper pipelines, real funding, and commercial traction that can deliver near-term catal...
CNS Pharmaceuticals reports Q1 results
* CNS Pharmaceuticals press release [https://seekingalpha.com/pr/20515241-cns-pharmaceuticals-reports-first-quarter-2026-financial-results-and-highlights-strategic] (CNSP [https://seekingalpha.com/sy...
Top Midday Gainers
Celcuity (CELC) reported late Friday positive topline results from a cohort of its phase 3 Viktoria- PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscri...
Get CNS Pharmaceuticals Inc fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
Best Offer
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
